Inmune Bio, Inc. (INMB)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 150K 300K 450K Q4 '21: 181K Q1 '22: 340K Q2 '22: 356K Q3 '22: 440K Q4 '22: 374K Q1 '23: 249K Q2 '23: 279K Q3 '23: 224K Q4 '23: 155K Q1 '24: 131K Q2 '24: 85K Q3 '24: 42K Q4 '24: 14K Q1 '25: 50K Q2 '25: 50K Q3 '25: 50K Q4 '25: 50K Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-60M -40M -20M 0 20M 40M 60M Q4 '18: -12.4M Q1 '19: -11.5M Q2 '19: -5.8M Q3 '19: -7.3M Q4 '19: -7.8M Q1 '20: -7.9M Q2 '20: -9.6M Q3 '20: -11.4M Q4 '20: -12.2M Q1 '21: -14.7M Q2 '21: -19.1M Q3 '21: -23.3M Q4 '21: -29.2M Q1 '22: -31.1M Q2 '22: -30.9M Q3 '22: -29.3M Q4 '22: -26M Q1 '23: -25.9M Q2 '23: -25.9M Q3 '23: -27M Q4 '23: -29.7M Q1 '24: -34.3M Q2 '24: -37.8M Q3 '24: -41.5M Q4 '24: -42.6M Q1 '25: -41.5M Q2 '25: -56.2M Q3 '25: -51.4M Q4 '25: -47.4M Q1 '26: -43.3M Q2 '26: -20.2M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Net Income TTM

-60M -40M -20M 0 20M 40M 60M Q4 '18: -12.4M Q1 '19: -11.5M Q2 '19: -5.7M Q3 '19: -7.2M Q4 '19: -7.7M Q1 '20: -7.8M Q2 '20: -9.6M Q3 '20: -11.2M Q4 '20: -12.1M Q1 '21: -14.6M Q2 '21: -19.1M Q3 '21: -23.9M Q4 '21: -30.3M Q1 '22: -32.7M Q2 '22: -32.9M Q3 '22: -31.1M Q4 '22: -27.3M Q1 '23: -26.9M Q2 '23: -26.6M Q3 '23: -27.4M Q4 '23: -30M Q1 '24: -34.5M Q2 '24: -37.7M Q3 '24: -41.3M Q4 '24: -42.1M Q1 '25: -40.8M Q2 '25: -55.5M Q3 '25: -49.9M Q4 '25: -45.9M Q1 '26: -41.6M Q2 '26: -18.4M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-45M -30M -15M 0 15M 30M 45M Q4 '18: -2.1M Q1 '19: -3.1M Q2 '19: -3.9M Q3 '19: -5.4M Q4 '19: -5.4M Q1 '20: -5M Q2 '20: -5.2M Q3 '20: -7M Q4 '20: -8.9M Q1 '21: -13M Q2 '21: -16.9M Q3 '21: -21.1M Q4 '21: -28.5M Q1 '22: -32.3M Q2 '22: -31.3M Q3 '22: -26.8M Q4 '22: -22.7M Q1 '23: -15M Q2 '23: -13.4M Q3 '23: -14.3M Q4 '23: -12M Q1 '24: -18.3M Q2 '24: -23M Q3 '24: -25.7M Q4 '24: -33.4M Q1 '25: -32.7M Q2 '25: -32.2M Q3 '25: -30.7M Q4 '25: -22.6M Q1 '26: -19.2M Q2 '26: -15M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Free Cash Flow TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Shares Outstanding Quarterly

0 10M 20M 30M Q1 '21: 14.3M Q2 '21: 15M Q3 '21: 17.3M Q1 '22: 17.9M Q2 '22: 17.9M Q3 '22: 17.9M Q1 '23: 17.9M Q2 '23: 17.9M Q3 '23: 18M Q1 '24: 18M Q2 '24: 19.3M Q3 '24: 20.2M Q1 '25: 22.5M Q2 '25: 23.3M Q3 '25: 26.6M Q1 '26: 26.6M Q2 '26: 26.7M Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-2.70 -1.80 -0.90 0.00 0.90 1.80 2.70 Q4 '18: -1.43 Q1 '19: -1.30 Q2 '19: -0.63 Q3 '19: -0.73 Q4 '19: -0.74 Q1 '20: -0.73 Q2 '20: -0.89 Q3 '20: -0.97 Q4 '20: -0.99 Q1 '21: -1.12 Q2 '21: -1.36 Q3 '21: -1.55 Q4 '21: -1.86 Q1 '22: -1.93 Q2 '22: -1.87 Q3 '22: -1.75 Q4 '22: -1.52 Q1 '23: -1.49 Q2 '23: -1.47 Q3 '23: -1.52 Q4 '23: -1.67 Q1 '24: -1.92 Q2 '24: -2.06 Q3 '24: -2.18 Q4 '24: -2.11 Q1 '25: -1.93 Q2 '25: -2.48 Q3 '25: -2.12 Q4 '25: -1.90 Q1 '26: -1.67 Q2 '26: -0.67 Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.